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Abstract
Dopamine (DA) and glutamate neurotransmission is thought
to be critical for psychostimulant drugs to induce immediate
early genes (IEGs) in the caudate-putamen (CPu). We report
here, however, that the ability of DA and glutamate NMDA
receptor antagonists to attenuate amphetamine-evoked c-fos
mRNA expression in the CPu depends on environmental
context. When given in the home cage, amphetamine induced
c-fos mRNA expression predominately in preprodynorphin
and preprotachykinin mRNA-containing neurons (Dyn-SP+
cells) in the CPu. In this condition, all of the D1R, D2R and
NMDAR antagonists tested dose-dependently decreased
c-fos expression in Dyn-SP+ cells. When given in a novel
environment, amphetamine induced c-fos mRNA in both Dyn-
SP+ and preproenkephalin mRNA-containing neurons (Enk+
cells). In this condition, D1R and non-selective NMDAR
antagonists dose-dependently decreased c-fos expression in
Dyn-SP+ cells, but neither D2R nor NR2B-selective NMDAR
antagonists had no effect. Furthermore, amphetamine-evoked
c-fos expression in Enk+ cells was most sensitive to DAR and
NMDAR antagonism; the lowest dose of every antagonist
tested significantly decreased c-fos expression only in these
cells. Finally, novelty-stress also induced c-fos expression in
both Dyn-SP+ and Enk+ cells, and this was relatively resistant
to all but D1R antagonists. We suggest that the mechanism(s)
by which amphetamine evokes c-fos expression in the CPu
varies depending on the stimulus (amphetamine vs. stress),
the striatal cell population engaged (Dyn-SP+ vs. Enk+ cells),
and environmental context (home vs. novel cage).
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Psychostimulant drugs are reported to induce immediate
early genes (IEGs) only in a specific subclass of projection
neurons in the caudate-putamen (CPu) – striatonigral GAB-
Aergic neurons that co-express mRNA for dopamine (DA)
D1Rs, preprodynorphin and preprotachykinin (Dyn-SP+
cells) (Berretta et al. 1992; Cenci et al. 1992; Berretta et al.
1993; Johansson et al. 1994; Ruskin and Marshall 1994; see
Harlan and Garcia 1998 for review). The ability of psycho-
stimulant drugs to induce IEGs in Dyn-SP+ cells involves
both DA and glutamate receptors, because both DA (Gray-
biel et al. 1990; Young et al. 1991; Ruskin and Marshall
1994; LaHoste et al. 2000) and glutamate receptor antago-
nists (Dragunow et al. 1991; Snyder-Keller 1991; Wang
et al. 1994; Konradi et al. 1996) markedly reduce amphet-
amine- and cocaine-evoked IEG expression in the CPu.
These studies have provided important information about the
neural circuits engaged by potentially addictive drugs, the
neurotransmitter systems involved, and about the initial steps
in the cascade of molecular changes that may contribute to
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drug experience-dependent plasticity (Nestler et al. 1993;
Hyman and Malenka 2001).
However, the selectivity of psychostimulant drug effects
on Dyn-SP+ cells may be more apparent than real, because it
is largely dependent on the context in which these drugs are
administered (Badiani et al. 1999). When given in the home
cage, amphetamine and cocaine induce c-fos expression
primarily in Dyn-SP+ cells, but when given in a novel
environment these drugs also induce c-fos expression in a
second subclass of striatal projection neurons – striatopallidal
GABAergic neurons that co-express mRNA for DA D2Rs
and preproenkephalin (Enk+ cells) (Jaber et al. 1995;
Badiani et al. 1999; Uslaner et al. 2001b, 2003). There is
no information regarding the neurotransmitter systems
responsible for psychostimulant-induced IEG expression in
Enk+ cells, because in previous studies drugs were only
given in the home cage. This is an important issue because
drugs are taken under many different conditions, and ‘set and
setting’ has an enormous effect on both the acute behavioral
and subjective effects of drugs, as well as on their ability to
induce forms of drug experience-dependent plasticity (Falk
and Feingold 1987; Robinson et al. 1998).
To begin to address which neurotransmitter systems
mediate psychostimulant-evoked IEG expression in different
striatal cell populations, we used dual in situ hybridization
histochemistry to study the effects of DA and glutamate
receptor antagonists on c-fos mRNA expression in both Dyn-
SP+ and Enk+ cells in the dorsomedial CPu under three
different conditions: (i) following exposure to a novel
environment (‘novelty stress’); (ii) following amphetamine
administration in the home cage; and (iii) following
amphetamine administration in a novel test cage. We report
that the effects of these antagonists on c-fos mRNA
expression in the CPu vary markedly as a function of
neuronal phenotype and environmental context.
Materials and methods
Subjects
Male Sprague–Dawley rats (Harlan Sprague Dawley, Indianapolis,
IN, USA), weighing 200–225 g upon arrival, were initially housed
singly in square, plastic, clear cages containing either pine shavings or
shredded paper bedding, and were allowed to acclimate to the animal
colony room for 1 week prior to any experimental manipulation. The
rooms were temperature- and humidity-controlled and maintained
on a 14 : 10 h light : dark cycle, with food and water available
ad libitum. All experimental procedures were approved by the
University of Michigan Committee on the Use and Care of Animals.
Groups and test procedures
Rats were randomly assigned to one of two groups. In all
experiments, one group of animals (HOME) was transferred from
the main animal colony to another room and placed individually into
orange, circular buckets (25 cm diameter at the base) with ground
corncob bedding on the floor. They remained in these cages for the
duration of the experiment. Animals in the other group (NOVEL)
remained in the main animal colony room. On the day of testing,
which was 7 days after the HOME animals were housed in orange
buckets, all animals in both groups received an intraperitoneal (i.p.)
injection (in their home cage) of either saline, SCH-23390 (in one
experiment 0.005 or 0.01, and another 0.05, 0.1 or 0.5 mg/kg),
SCH-39166 (0.01, 0.03, 0.1, or 0.3 mg/kg), L-741,262 (2.5, 5
or 10 mg/kg) (±)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic
acid (CPP; 1 or 10 mg/kg), ifenprodil (1 or 10 mg/kg) or MK-801
(0.5 or 1 mg/kg). Thirty minutes later, animals in the HOME groups
received an injection of saline or 2 mg/kg of d-amphetamine sulfate
in their home cage (i.e. the orange circular buckets) and animals in
the NOVEL groups were transported to a testing room where they
received an injection of saline or amphetamine and were immedi-
ately placed into orange circular buckets physically identical to
those in which animals in the HOME groups lived (but distinct from
their own home cages). A third untreated group was used as a
control group to assess basal levels of c-fos mRNA expression.
These animals remained in the animal colony room during testing
and received no injections. Fifty minutes after the second injection,
all animals were decapitated in the absence of further drug treat-
ments, their brains removed, frozen in isopentane and stored at
) 70C. Each antagonist was tested in separate experiments, with their
own control groups, except animals given CPP and the lower doses of
SCH-23390 (0.005–0.05 mg/kg), which were tested in the same
experiment. The tissue from each experiment was processed for dual
in situ hybridization histochemistry (dISH) at the same time.
Dual in situ hybridization methods
The brains were sectioned using a cryostat and 16-lm coronal
sections were thaw-mounted onto polylysine-coated slides and
stored at ) 70C until processed for dISH. The method was a
modification of that described by Curran and Watson (1995). Slides
containing four tissue sections were processed using a [35S]UTP and
–CTP labeled riboprobe complementary to c-fos (680-mer, courtesy
of Dr T. Curran, St. Jude Children’s Research Hospital, Memphis,
TN, USA) and a digoxigenin-UTP labeled riboprobe complement-
ary to preprodynorphin, preprotachykinin (substance P) or prepro-
enkephalin (733-mer, 567-mer and 693-mer, respectively; courtesy
of Dr J. Douglass, Amgen, Thousand Oaks, CA, USA). The
radioactive riboprobe was generated by incubating linearized c-fos
DNA (1 lg) at 37C for 1.5 h in 1 · transcription buffer, 80 lCi
of [a-35S]UTP (100 Ci/mM; 20 mCi/mL; Amersham, Arlington
Heights, IL, USA), 120 lCi of [a-35S]CTP (800 Ci/mM; 40 mCi/mL;
Amersham), 400 lM GTP, 400 lM ATP, 8 mM dithiothreitol (DTT),
20 U RNase Inhibitor and 6 U of T7 RNA polymerase. The non-
radioactive riboprobes were generated by incubating linearized
preprodynorphin, preprotachykinin or preproenkephalin DNA
(1 lg) at 37C for 1.5 h in 1 · transcription buffer, 320 lM
digoxigenin-UTP (dig-UTP; Boehringer, Mannheim, Germany),
80 lM UTP, 400 lM GTP, 400 lM ATP, 400 lM CTP, 10 mM DTT,
40 U RNase inhibitor and 200 U of T7 RNA polymerase. The
resulting probes were incubated at 22C with 125 U of Rnase-free
DNase for 15 min and then separated from free nucleotides on
Sephadex G50-50 columns.
Prior to hybridization, tissue sections were fixed in 4%
phosphate-buffered paraformaldehyde for 1 h at room temperature,
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rinsed three times in 2 · SSC, placed into a solution of 0.1 M
triethanolamine/0.25% acetic acid for 10 min, rinsed in water and
dehydrated in a series of graded alcohols (50–100%). The
35S-labeled and dig-UTP labeled probes were diluted in hybridiza-
tion buffer (50% formamide, 10% dextran sulfate, 3 · SSC, 50 mM
sodium phosphate, pH 7.4, 1 · Denhardt’s solution and 10 mg/mL
yeast tRNA) to give an approximate concentration of 2.5–3.0 · 106
d.p.m./70 lL. The appropriate concentration of the non-radioactive
probe was determined based on pilot studies. Slides were cover-
slipped with diluted probe (70 lL) and placed in hybridization trays
lined with filter paper dampened with 50% formamide/50% water.
The trays were sealed and incubated at 55C for 16 h. Coverslips
were floated off in 2 · SSC and the slides were rinsed three times in
2 · SSC. The slides were then incubated in RNase A (200 lg/mL)
at 37C for 1 h, rinsed in 2 ·, 1 ·, 0.5 ·, incubated in 0.1 · SCC at
65C for 1 h and then cooled to room temperature. The slides were
rinsed in 0.1 M sodium phosphate buffer (pH 7.4), incubated with
shaking for 1 h at room temperature in a blocking solution (0.25%
carageenan, 0.5% Triton-X, 0.1 M sodium phosphate buffer, and
then incubated with shaking overnight at room temperature with an
antibody against digoxigenin, conjugated to alkaline phosphatase
(sheep antidig AP, Fab fragments; Boehringer) that was diluted
1 : 20 000 in a blocking solution. Slides were then incubated at
room temperature with shaking for two times (1 h each) in 0.1 M
sodium phosphate buffer, two times (30 min each) in Tris-buffered
saline and rinsed in alkaline substrate buffer (ASB) 100 mM Tris
base, 50 mM NaCl, 50 mM MgCl2, pH 9.5. The color reaction was
carried out in the dark at room temperature in ASB containing 5%
polyvinyl alcohol (Sigma, St Louis, MO, USA), 0.025% levam-
isole (Sigma) and 2% NBT/BCIP (Boehringer). After  4 h for
preproenkephalin and  24 h for preprodynorphin and preprotach-
ykinin, the color reaction was stopped by washing the slides
extensively in water, incubating in 0.1 M glycine, 0.2% Triton-X
100, pH 2.2 for 10 min at room temperature and rinsing in water.
Slides were then fixed in 2.5% glutaraldehyde for 2 h, rinsed in
water and air-dried.
Slides were exposed to X-ray film (Kodak Biomax MR,
Rochester, NY, USA) and then dipped in emulsion (Ilford KD-5,
Polysciences) and stored in light-tight boxes at 4C for 5–6 days.
Slides were developed (Kodak D-19) for 2 min at 17C, rinsed in
water and fixed (Kodak Rapid Fix) for 3 min at 17C. Slides were
then washed extensively in water, dehydrated in a series of graded
alcohols (50–100%), washed extensively in xylene and coverslipped
with Permount mounting medium.
Control experiments using sense probes or tissue pre-treated with
Rnase A (200 lg/mL at 37C for 1 h) were performed to ensure
probe specificity and no binding was observed with either control. In
addition, co-localization experiments were conducted with prepro-
dynorphin mRNA and preprotachykinin mRNA, preprodynorphin
mRNA and preproenkephalin mRNA, as well as preprotachykinin
mRNA and preproenkephalin mRNA. The preprodynorphin and
preprotachykinin probes co-localized, whereas the preproenkephalin
probe did not co-localize with either the preprodynorphin probe or
the preprotachykinin probe.
Quantification of c-fos mRNA and data analysis
Initial quantification of c-fos mRNA expression was conducted on
autoradiographs of rostral (0.0 mm to bregma) and caudal sections
(0.8 mm posterior to bregma) (Paxinos and Watson 1998) as
described previously (Badiani et al. 1998). A similar pattern of c-fos
mRNA expression for control groups (i.e. groups not receiving
antagonist pre-treatment) and a similar effect of antagonist pre-
treatment was found across both levels and in multiple subregions
(dorsomedial, dorsolateral and ventral) within each level of the CPu.
The dorsomedial portion of sections 0.8 mm posterior to bregma
(see Fig. 1) was selected for further analysis because the magnitude
of c-fos mRNA expression was greatest at this level of the CPu in
the present study and we previously found the largest effect of
Fig. 1 Expression of c-fos mRNA in the dorso-caudal CPu after
exposure to a novel environment, amphetamine or both. The illustration
in the upper left panel contains boxes that depict the area of the dorsal
CPu that was quantified (total area ¼ 0.5 mm2). Note that to simplify
data presentation the mean value of the control group has been
subtracted, and therefore, in all graphs basal levels of expression are
indicated by a value of zero, and values above zero represent an
increase in the number of c-fos+ cells, relative to baseline. (a) The
mean (± SEM) number of c-fos+ cells as a function of treatment
condition. For all treatment conditions, there was a significant increase
in the number of c-fos+ cells over baseline (one-sample t-tests;
novelty stress group, t ¼ 17.42, p < 0.0001; home/amphetamine
group, t ¼ 16.79, p < 0.0001; novel/amphetamine group, t ¼ 21.74,
p < 0.0001). The number of c-fos+ cells was significantly higher in the
novel/amphetamine group than in any other group (one-way ANOVA
followed by Bonferroni’s-tests; F2,72 ¼ 86.30, p < 0.0001). (b) The
mean (± SEM) number of c-fos+ cells that were also Dyn-SP+ (white
bars) or Enk+ (black bars). For all treatment conditions, there was a
significant increase in the number of both c-fos/Dyn-SP+ cells and
c-fos/Enk+ cells over baseline (all p < 0.0001). For all conditions, there
was also a significant effect of cell type; that is, there were more c-fos/
Dyn-SP+ cells than c-fos/Enk+ cells (t ¼ 2.6–11.8, p < 0.01). However,
the increase in the total number of c-fos+ cells seen in animals given
amphetamine in the novel environment was due to an increase in the
number of c-fos/Enk+ cells (p < 0.001), not c-fos/Dyn-SP+ cells. *, dif-
fers from the home/amphetamine group (p < 0.001, Bonferroni test).
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environmental context on amphetamine-evoked c-fos mRNA
expression at this level of the CPu (Badiani et al. 1998; Uslaner
et al. 2001b). Quantification was carried out at 40 · magnification
using a Leica microscope (Letiz DMR, Wetzler, Germany) on
sections from three to seven animals/group. In the dorso-caudal
CPu, the total number of single- and double-labeled cells was
counted in four 250-lm2 grids of each hemisphere (for a total of
eight grids; see Fig. 1 inset). 35S-labeled cells (containing c-fos
mRNA) appeared as silver grains under darkfield conditions and
dig-labeled cells (containing preprodynorphin, preprotachykinin or
preproenkephalin mRNA) appeared as purple precipitate under
brightfield conditions. Sections were quantified by an experimenter
blind to the experimental conditions. Only 35S-labeled cells that
contained dense clusters of silver grains (i.e. at least 10 silver grains/
cell) and dig-labeled cells that were uniformly darkly stained (i.e. at
least 10 times above background staining) were considered to be
positively labeled cells.
Drugs
The DA D1R antagonists R(+)-SCH-23390 (Sigma) and SCH-
39166 (generously donated by Schering-Plough Research Institute,
Kenilworth, NJ, USA), the competitive NMDAR antagonist CPP
(Sigma), the non-competitive NMDAR antagonist (+)-MK-801
(Sigma) and d-amphetamine sulfate (Sigma) were dissolved in 0.9%
saline and injected in a volume of 1 mL/kg. The DA D2R antagonist
L-741,262 (Tocris Cookson, Ballwin, MO, USA) was dissolved in a
small amount of glacial acetic acid, diluted in sterile water, the pH
adjusted to 4.5 with sodium hydroxide and injected in a volume of
1.56, 3.13, or 6.25 mL/kg. The NR2B subunit-selective NMDAR
antagonist ifenprodil (Sigma) was dissolved in sterile water and
injected in a volume of 1 or 8 mL/kg. All drugs were administered
by i.p. injection. SCH-23390 and MK-801 were chosen because
previous studies on psychostimulant-evoked IEG expression used
these drugs, allowing us to compare our results with the existing
literature. SCH-39166 was chosen because it has very high affinity
for D1Rs and very low affinity for serotonin (5-HT) or D2Rs (Duffy
et al. 2000). L-741,262 was chosen because it is highly selective for
D2Rs over D3 and D4 receptors and by itself has only moderate
effects on c-fos expression (LaHoste et al. 2000). CPP was chosen
because it circumvents some of the problems associated with the
complex pharmacological profile of the non-competitive NMDAR
antagonist, MK-801. Ifenprodil was chosen because it is selective
for NR2B subunit-containing NMDARs, whereas the other
NMDAR antagonists tested are non-selective. The dose ranges
and injection times for each antagonist were based on effective
doses reported in the existing literature, and on pilot studies. The
dose of amphetamine was chosen because it has been shown to
induce greater c-fos mRNA expression in the CPu in animals given
amphetamine in a novel environment than in animals given
amphetamine at home (Badiani et al. 1998). All drug weights refer
to the weight of the salts.
Statistical analysis
As expected from previous studies, the level of c-fos mRNA
expression in the untreated group and the group that received saline
injections at home was very low, and these groups did not differ.
Therefore, these two groups were pooled. In addition, in all
experiments except the one with L-741,262, the antagonist
pre-treatment (without amphetamine) did not effect basal levels of
c-fos mRNA expression, so these groups were also pooled with the
untreated and home/saline groups. This produced a single control
group that provided an index of basal c-fos mRNA expression. In
the case of the L-741,262 experiment there were two control groups.
One control group contained untreated and home/saline animals that
did not receive L-741,262 pre-treatment (i.e. they received saline
pre-treatment). The mean value for this group was subtracted from
each animal not receiving L-741,262 pre-treatment in the other
conditions. The second control group contained home/saline animals
that received L-741,262 pre-treatment (i.e. they received 2.5, 5 or
10 mg/kg L-741,262). The mean value for this group was subtracted
from each animal receiving L-741,262 pre-treatment in the other
conditions. To simplify data presentation, the mean value for the
control group was subtracted from each animal, and thus, if the
mean for any group differs significantly from zero (tested using
planned one-sample t-tests) this indicates a significant change in
c-fos mRNA expression, relative to baseline. Group differences in
the total number of c-fos+ cells, the number of double-labeled c-fos/
Dyn-SP+ cells or the number of double-labeled c-fos/Enk+ cells
were tested using one-way analyses of variances (ANOVA) followed
by Bonferroni’s or Dunnett’s posthoc tests. Differences in the
number of c-fos/Dyn-SP+ versus c-fos/Enk+ in the same group were
analyzed using unpaired t-tests. For all comparisons, a¼ 0.05.
Results
Effect of environmental context on c-fos mRNA
expression in Dyn-SP and Enk+ cells
To assess the overall effect of environmental novelty on c-fos
mRNA (c-fos) expression in cells containing preprodynor-
phin or preprotachykinin mRNA (these will be called Dyn-
SP+ cells) or cells containing preproenkephalin mRNA
(these will be called Enk+ cells), data for saline-pre-treated
(i.e. not antagonist-pre-treated) animals from four separate
dISH experiments were pooled. These data are summarized
in Table 1 and Fig. 1. Table 1 shows the total number of
cells counted (summed across all animals) and the percent of
double-labeled cells (i.e. those positive for c-fos that were
also Dyn-SP+ or Enk+, divided by the total number of c-fos+
cells), as a function of treatment condition. Figure 1 shows
the mean (± SEM) number of c-fos+ cells (top) and the mean
number of double-labeled cells (bottom), as a function of
treatment condition. In Fig. 1, the mean number of c-fos+
cells in the control group (untreated plus home–saline
group), which was quite small (see Table 1), was subtracted
from the value for each animal in the other groups to simplify
data presentation and analysis. Thus, on Fig. 1, a value of
zero indicates basal levels of c-fos expression and any mean
that is statistically greater than zero represents a significant
increase in the number of c-fos+ cells, relative to this baseline
(see figure legends for statistics).
Figure 1 (top) shows that all treatments significantly
increased the number of c-fos+ cells, although there were
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also significant group differences. The number of c-fos+ cells
was significantly higher in animals given amphetamine in a
novel environment than in either animals given saline in the
novel environment or animals given amphetamine at home.
Figure 1 (bottom) shows the specific cell types (i.e. Dyn-SP+
vs. Enk+) that expressed c-fos and Fig. 2 provides represen-
tative examples of c-fos/Enk+ cells in the home and novel
conditions. Note that the number of c-fos/Dyn-SP+ and c-fos/
Enk+ cells accounts for all but a few percent of the total
number of c-fos+ cells (Table 1), consistent with the fact that
these cells represent 90–95% of all neurons in the CPu.
However, the proportion of c-fos+ cells that were also Dyn-
SP+ or Enk+ varied significantly as a function of treatment
condition. When given at home, amphetamine induced c-fos
expression predominately in Dyn-SP+ cells (87% of c-fos+
cells were Dyn-SP+ and only 11% were Enk+; Table 1,
Fig. 1b). The increase in the total number of c-fos+ cells seen
when amphetamine was given in a novel environment was
due almost entirely to an increase in the number of c-fos/
Enk+ cells (Fig. 1b). Thus, when amphetamine was given in
the novel environment, the number of c-fos/Dyn-SP+ cells
accounted for only 61% of the total number of c-fos+ cells
and the percent of c-fos/Enk+ cells rose from 11% to 35% of
c-fos+ cells (Table 1). Mere exposure to the novel environ-
ment produced a lower level of c-fos expression compared
with animals given amphetamine, but interestingly, the
proportion of c-fos/Dyn-SP+ versus c-fos/Enk+ cells was
similar to that in animals given amphetamine in the novel
environment (Table 1 and Fig. 1).
Effect of the DA D1R antagonists, SCH-23390
and SCH-39166, on c-fos mRNA expression in Dyn-SP+
and Enk+ cells
Figure 3 shows the effect of pre-treatment with the DA
D1-selective receptor antagonist SCH-23390 on c-fos
expression. The top panels show that SCH-23390 dose-
dependently reduced the total number of c-fos+ cells in all
groups. The bottom panels show that the effectiveness of
SCH-23390 differed depending on treatment condition. In
animals given amphetamine at home (panel E) nearly all
c-fos+ cells were also Dyn-SP+, and the highest dose of
SCH-23390 reduced the number of c-fos/Dyn-SP+ cells,
although this effect did not quite reach statistical signifi-
cance (p < 0.1; but see below for the effect of higher
doses). Given that there were so few c-fos/Enk+ cells in this
condition (panel E), the likelihood of floor effects is high
and so the effect of SCH-23390 and the other antagonists
on c-fos/Enk+ cells for this condition were not assessed.
Amphetamine given in the novel environment (panel F)
induced c-fos expression in a comparable number of Dyn-
SP+ and Enk+ cells. SCH-23390 dose-dependently reduced
the number of c-fos/Enk+ cells. However, the effect of these
doses of SCH-23390 on the number of c-fos/Dyn-SP+ cells
was not statistically significant. In animals given saline in
the novel environment (panel D), SCH-23990 had no
significant effect on c-fos expression in either type of cell.
In a second independent experiment, the effect of higher
doses of SCH-23390 (0.05, 0.1 and 0.5 mg/kg) was
examined using the same experimental design. All three
of these higher doses reduced c-fos expression to basal
levels in all groups (data not shown).
Figure 4 shows the effect of the highly selective DA D1R
antagonist SCH-39166 on c-fos expression. The top panels
show that SCH-39166 dose-dependently reduced the total
number of c-fos+ cells in all conditions, although in animals
given saline in the novel environment this effect reached
statistical significance only at one dose (0.1 mg/kg). The
bottom panels show that the effectiveness of SCH-39166
differed depending on cell type and drug treatment. In
animals given amphetamine at home (panel E) or in the novel
environment (panel F) SCH-39166 dose-dependently dec-
reased the number of c-fos/Dyn-SP+ cells. SCH-39166 was
especially effective in decreasing the number of c-fos/Enk+
cells in the novel condition. Indeed, the lowest dose tested
significantly reduced the number of c-fos/Enk+ cells, but not
the number of c-fos/Dyn-SP+ cells (panel F). In animals
given saline in the novel environment (panel D) there was no
statistically significant effect of SCH-39166 on c-fos expres-
sion in either type of cell.
Effect of the DA D2R antagonist L-741,262 on c-fos
mRNA expression in Dyn-SP+ and Enk+ cells
Figure 5 shows the effect of pre-treatment with the DA D2R
antagonist L-741,262 on c-fos expression. The figure inset
Table 1 The co-localization of c-fos+ cells and Dyn-SP+ cells (top) or
Enk+ cells (bottom) in the dorso-caudal CPu, as a function of treat-
ment condition
Group n c-fos+ Dyn/SP+ Double Double (%)
Control 24 241 3676 206 87.0 ± 2.5
Amph (Home) 25 1397 4046 1210 87.4 ± 1.2
Novelty 22 753 3402 510 68.3 ± 1.7
Amph + novelty 25 2106 3926 1292 61.4 ± 1.1
Group n c-fos+ Enk+ Double Double (%)
Control 23 148 4410 24 14.1 ± 2.7
Amph (Home) 25 1313 4696 141 11.1 ± 1.1
Novelty 24 879 4804 283 33.2 ± 1.5
Amph + novelty 24 2179 4749 772 35.4 ± 0.9
The columns (left to right) show the group, number of animals/group,
the total number of cells counted (summed across all animals) that
were only c-fos+, the total number of cells that were only Dyn-SP+
(or Enk+) and the total number of cells that were both c-fos+ and
Dyn-SP+ (or Enk+). For each animal, the percent of all c-fos+ cells that
were double-labeled was calculated and the mean (± SEM) per cent of
double-labeled cells is shown in the last column.
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(top) shows that by itself L-741,262 slightly increased the
total number of c-fos+ cells in animals given saline at home
(i.e. basal levels of expression), although this effect reached
statistical significance only at the highest dose used.
Nevertheless, L-741,262 dose-dependently reduced the total
number of c-fos+ cells in animals given amphetamine,
regardless of environmental condition. There was no effect of
L-741,262 in animals given saline in the novel environment
(top panels). The bottom panels show that the effectiveness
of L-741,262 differed depending on cell type and treatment
condition. The figure inset (bottom) shows that L-741,262 by
itself dose-dependently increased basal levels of c-fos
expression in both Dyn-SP+ and Enk+ cells, although this
effect reached statistical significance only in Enk+ cells and
only at the highest dose tested. In animals given amphetam-
ine at home (panel E), L-741,262 dose-dependently reduced
the number of c-fos/Dyn-SP+ cells. In animals given amphet-
amine in the novel environment (panel F), L-741,262 dose-
dependently reduced the number of c-fos/Enk+ cells, but had
no significant effect on the number of c-fos/Dyn-SP+ cells.
In animals given saline in the novel environment (panel D),
L-741,262 had no significant effect on c-fos expression in
either type of cell.
Effect of the NMDAR antagonists CPP, ifenprodil
and MK-801 on c-fos mRNA expression in Dyn-SP+
and Enk+ cells
The effect of pre-treatment with the NMDAR antagonist
CPP on c-fos expression is depicted in Fig. 6. The top
panels show that CPP dose-dependently reduced the total
number of c-fos+ cells in animals given amphetamine at
home or in the novel environment. The effect of CPP in
animals given saline in the novel environment was not
statistically significant. The bottom panels show that the
effectiveness of CPP differed depending on cell type and
treatment condition. In animals given amphetamine at home
(panel E), CPP reduced the number of c-fos/Dyn-SP+ cells
only at the highest dose tested. Similarly, in animals given
amphetamine in the novel environment (panel F), CPP
reduced the number of c-fos/Dyn-SP+ cells only at the
highest dose tested. In contrast, both doses of CPP
markedly reduced the number of c-fos/Enk+ cells in the
Fig. 2 Representative histological plates
depicting sections from the CPu that are
double-labeled for c-fos mRNA and pre-
proenkephalin mRNA. The panels on the
left are from animals given amphetamine at
home and the panels on the right are from
animals given amphetamine in the novel
environment. (Top) Brightfield images in
which Enk+ cells are indicated by purple
precipitate. (Middle) Darkfield images in
which c-fos+ cells are indicated by clusters
of silver grains. (Bottom) Overlay of bright-
field and darkfield images. Up arrows indi-
cate single-labeled cells (c-fos+ or Enk+).
Right arrows indicate double-labeled cells
(c-fos/Enk+).
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novel condition. In animals given saline in the novel
environment (panel D), CPP had no significant effect on
c-fos expression in either type of cell.
In a second independent experiment, the effect of MK-801
was examined using the same experimental design. At the
doses tested (0.5 and 1 mg/kg) MK-801 reduced c-fos
expression to basal levels in all groups (data not shown).
Neither CPP nor MK-801 distinguishes between
NMDARs that contain the main types of NR2 subunits in
the striatum (i.e. NR2A and NR2B). However, NMDARs
containing NR2B subunits have been associated with
enhanced plasticity (Quinlan et al. 1999; Tang et al. 1999);
and therefore, we also examined the effect of ifenprodil, a
NR2B subunit-selective NMDAR antagonist. Figure 7
shows the effect of pre-treatment with ifenprodil on c-fos
expression. The top panels show that ifenprodil reduced the
total number of c-fos+ cells in animals given amphetamine
regardless of environmental condition. The effect of ifen-
prodil in animals given saline in the novel environment was
not statistically significant. The bottom panels show that the
effectiveness of ifenprodil differed depending on cell type
and treatment condition. In animals given amphetamine at
home (panel E), the highest dose of ifenprodil markedly
decreased the number of c-fos/Dyn-SP+ cells. In animals
given amphetamine in the novel environment (panel F),
ifenprodil had no effect on the number of c-fos/Dyn-SP+
cells, but both doses significantly decreased the number of
c-fos/Enk+ cells. In animals given saline in the novel
environment (panel D), ifenprodil had no significant effect on
c-fos expression in either type of cell.
Discussion
Regulation of c-fos expression in Dyn-SP+ cells evoked
by amphetamine given at home
When given in the home cage, amphetamine evoked c-fos
expression primarily in Dyn-SP+ cells (i.e. 87% of c-fos+
Fig. 3 Expression of c-fos mRNA in the dorso-caudal CPu after pre-
treatment with the D1R antagonist SCH-23390. Top panels (a–c)
depict the total number of c-fos+ cells and bottom panels (d–f) depict
the number of c-fos/Dyn-SP+ cells (white circles) or c-fos/Enk+ cells
(black squares) as a function of treatment and environmental condi-
tion. SCH-23390 significantly decreased the total number of c-fos+
cells in all conditions (panel a, F2,9 ¼ 14.14, p ¼ 0.002; panel b,
F2,15 ¼ 7.86, p ¼ 0.005; panel c, F2,14 ¼ 7.11, p ¼ 0.01). There was
no significant effect of SCH-23390 on the number of c-fos/Dyn-SP+ in
the novelty stress or novel/amphetamine groups (panel d, F2,9 ¼ 2.13,
p ¼ 0.17; panel f, F2,14 ¼ 1.96, p ¼ 0.18), but SCH-23390 did have a
significant effect on the home/amphetamine group (panel e,
F2,14 ¼ 4.23, p ¼ 0.04). SCH-23390 decreased the number of c-fos/
Enk+ cells only when amphetamine was given in the novel environ-
ment (panel d, F2,9 ¼ 2.81, p ¼ 0.11; panel e, F2,15 ¼ 2.93, p ¼ 0.08;
panel f, F2,13 ¼ 15.80, p ¼ 0.0003). *, differs from 0 mg/kg (p < 0.05,
Dunnett’s-test); , this paired comparison was not quite statistically
significant (p < 0.1, Dunnett’s-test), although the overall ANOVA was
significant (above).
Fig. 4 Expression of c-fos mRNA in the dorso-caudal CPu after pre-
treatment with the D1R antagonist SCH-39166. Top panels (a–c)
depict the total number of c-fos+ cells and bottom panels (d–f) depict
the number of c-fos/Dyn-SP+ cells (white circles) or c-fos/Enk+ cells
(black squares) as a function of treatment and environmental condi-
tion. SCH-39166 significantly decreased the total number of c-fos+
cells in all conditions (panel a, F4,13 ¼ 4.60, p ¼ 0.02; panel b,
F4,25 ¼ 20.82, p < 0.0001; panel c, F4,25 ¼ 48.03, p < 0.0001). SCH-
39166 significantly decreased the number of c-fos/Dyn-SP+ in the
home/amphetamine group (panel e, F4,25 ¼ 17.16, p < 0.0001), the
novel/amphetamine group (panel f, F4,25 ¼ 23.61, p < 0.0001) but not
the novelty stress group (panel d, F4,13 ¼ 2.11, p ¼ 0.14). Similarly,
SCH-39166 significantly decreased the number of c-fos/Enk+ cells in
the novel/amphetamine group (panel f, F4,21 ¼ 86.87, p < 0.0001) but
not the novelty stress group (panel d, F4,13 ¼ 2.42, p ¼ 0.10). *, differs
from 0 mg/kg (p < 0.05, Dunnett’s-test).
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cells were also Dyn-SP+). Under these conditions, all of the
DAR and NMDAR antagonists tested dose-dependently
decreased c-fos expression in these cells. This is consistent
with the existing literature on the effects of DA (Graybiel
et al. 1990; Berretta et al. 1992; Cenci et al. 1992; Ruskin
and Marshall 1994; Drago et al. 1996; Moratalla et al. 1996;
LaHoste et al. 2000) and glutamate receptor antagonists
(Dragunow et al. 1991; Snyder-Keller 1991; Cenci and
Bjorklund 1993; Wang et al. 1994; Vargo and Marshall
1995; Konradi et al. 1996) on psychostimulant-evoked c-fos
expression. There is a general consensus, therefore, that
when given at home psychostimulants induce c-fos in Dyn-
SP+ cells via D1R activation of the cAMP/PKA signaling
cascade, and this is further regulated by D2Rs and NMDARs
(Graybiel et al. 1990; Konradi et al. 1994; Ruskin and
Marshall 1994; Cole et al. 1995; Konradi et al. 1996;
LaHoste et al. 2000; see McGinty and Wang 1998 for
review).
Regulation of c-fos expression in Dyn-SP+ cells evoked
by amphetamine given in a novel environment
When given in a novel environment, amphetamine-induced
c-fos expression in both Dyn-SP+ and Enk+ cells (i.e. 61%
of c-fos+ cells were Dyn-SP+ and 35% of c-fos+ cells were
Enk+). The mechanisms by which psychostimulants given
in a novel environment induce IEGs in Dyn-SP+ cells have
never been studied. We found that under this condition
D1R antagonists and non-selective NMDAR antagonists
decreased c-fos expression in Dyn-SP+ cells but there was
no effect of D2R or NR2B-selective NMDAR antagonists.
Thus, when amphetamine was given at home, all of the
antagonists tested reduced c-fos expression in Dyn-SP+
cells, but when amphetamine was given in a novel
environment, D2R and NR2B-selective NMDAR antago-
nists did not.
Fig. 5 Expression of c-fos mRNA in the dorso-caudal CPu after pre-
treatment with the D2R antagonist L-741,262. Top panels (a–c) depict
the total number of c-fos+ cells and bottom panels (d–f) depict the
number of c-fos/Dyn-SP+ cells (white circles) or c-fos/Enk+ cells
(black squares) as a function of treatment and environmental condi-
tion. L-741,262 significantly increased basal levels of c-fos expression
(inset, F3,13 ¼ 3.56, p ¼ 0.04) but this effect was significant only in
c-fos/Enk+ cells (inset, F3,12 ¼ 4.25, p ¼ 0.03). L-741,262 significantly
decreased the total number of c-fos+ cells in the home/amphetamine
group (panel b, F3,20 ¼ 7.97, p ¼ 0.001), the novel/amphet-
amine group (panel c, F3,21 ¼ 6.21, p ¼ 0.004) but not the novelty
stress group (panel a, F3,14 ¼ 0.22, p ¼ 0.88). Interestingly,
L-741,262 significantly decreased the number of c-fos/Dyn-SP+ in the
home/amphetamine group (panel e, F3,18 ¼ 3.45, p ¼ 0.04) but nei-
ther the novel/amphetamine group (panel f, F3,18 ¼ 0.33, p ¼ 0.81)
nor the novelty stress group (panel d, F3,12 ¼ 0.57, p ¼ 0.65). How-
ever, L-741,262 significantly decreased the number of c-fos/Enk+ cells
in the novel/amphetamine group (panel f, F3,21 ¼ 7.14, p ¼ 0.002) but
not the novelty stress group (panel d, F3,14 ¼ 0.10, p ¼ 0.96). *, differs
from 0 mg/kg (p < 0.05, Dunnett’s-test).
Fig. 6 Expression of c-fos mRNA in the dorso-caudal CPu after pre-
treatment with the NMDAR antagonist CPP. Top panels (a–c) depict
the total number of c-fos+ cells and bottom panels (d–f) depict the
number of c-fos/Dyn-SP+ cells (white circles) or c-fos/Enk+ cells
(black squares) as a function of treatment and environmental condi-
tion. CPP significantly decreased the total number of c-fos+ cells in the
home/amphetamine group (panel b, F2,15 ¼ 12.41, p ¼ 0.001), the
novel/amphetamine group (panel c, F2,15 ¼ 19.15, p < 0.0001) but not
the novelty stress group (panel a, F2,9 ¼ 2.14, p ¼ 0.17). Likewise,
CPP significantly decreased the number of c-fos/Dyn-SP+ in the
home/amphetamine group (panel e, F2,15 ¼ 8.78, p ¼ 0.003), the
novel/amphetamine group (panel f, F2,15 ¼ 10.73, p ¼ 0.001) but not
the novelty stress group (panel d, F2,9 ¼ 0.04, p ¼ 0.99). CPP also
significantly decreased the number of c-fos/Enk+ cells in the novel/
amphetamine group (panel f, F2,15 ¼ 19.92, p < 0.0001) but not the
novelty stress group (panel d, F2,9 ¼ 0.66, p ¼ 0.54). *, differs from
0 mg/kg (p < 0.05, Dunnett’s-test).
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It is unclear what accounts for the different effects of DA
D2R and NR2B-selective NMDAR antagonists on amphet-
amine-evoked c-fos expression, as a function of environ-
mental condition. One possibility is that environmental
novelty enhances amphetamine-stimulated DA release and
therefore higher doses of these antagonists are required under
this condition. However, environmental novelty did not
significantly increase the total number of amphetamine-
evoked c-fos/Dyn-SP+ cells (present study), and microdial-
ysis studies have shown that environmental novelty has no
effect on amphetamine-evoked DA release in the CPu or
nucleus accumbens (Badiani et al. 1997, 1998).
Psychostimulants are thought to induce IEG expression in
Dyn-SP+ cells via D1R activation of the cAMP/PKA
signaling cascade (Graybiel et al. 1990; Konradi et al.
1994; Cole et al. 1995); and therefore, exposure to environ-
mental novelty may facilitate activation of this intracellular
signaling cascade. Perhaps exposure to a novel environment
enhances the binding affinity of DA for DARs or increases
DAR reserves on Dyn-SP+ cells, either through an increase
in receptor density or through alterations in G-protein/
receptor coupling. These changes would decrease the amount
of DA required to trigger D1R-mediated intracellular sign-
aling cascades that induce IEG expression in Dyn-SP+ cells,
and consequently higher doses of antagonists would be
needed to block the effect. This is an unlikely explanation,
however, given that there were no significant differences in
the ability of the D1R antagonists to block amphetamine-
evoked c-fos expression in Dyn-SP+ cells under either
condition and that doses of D2R or NR2B subunit-selective
NMDAR antagonists that were capable of blocking c-fos
expression in Dyn-SP+ cells when amphetamine was
administered in the home cage had no effect on c-fos
expression in Dyn-SP+ cells when amphetamine was
administered in the novel environment.
This leaves the intriguing possibility that the mechan-
ism(s) by which amphetamine induces c-fos expression in
Dyn-SP+ cells differs as a function of the context in which it
is administered. Perhaps environmental novelty recruits other
neurotransmitter systems that interact with D1R-mediated
intracellular signaling cascades. For example, mere exposure
to a novel environment markedly activates the neocortex,
presumably engaging corticostriatal glutamate afferents to
the CPu, and this effect is amplified when amphetamine is
given in a novel environment (Badiani et al. 1998; Uslaner
et al. 2001a). Although the activation of corticostriatal
glutamate afferents induces c-fos primarily in Enk+ cells
(Berretta et al. 1997; Parthasarathy and Graybiel 1997;
Sgambato et al. 1997), direct intrastriatal infusions of
glutamate agonists or cortical stimulation can also induce
c-fos in a subpopulation of striatal interneurons that are
positive for NADPH-diaphorase (Berretta et al. 1992, 1997).
Interestingly, these interneurons do not contain D2Rs and
contain low levels of NR2B subunit-containing NMDARs
(Yung et al. 1995; Standaert et al. 1999). Moreover, psy-
chostimulant administration at home does not evoke c-fos
expression in NADPH-diaphorase+ interneurons (Berretta
et al. 1992). Thus, it is conceivable that these interneurons
are activated by glutamate following exposure to a novel
environment and are capable of modulating amphetamine-
evoked c-fos expression in Dyn-SP+ cells, likely via
neuronal nitric oxide synthase (nNOS) signaling mechanisms
(Kawaguchi et al. 1995).
It is also possible that additional neurotransmitter
systems interact with DA and glutamate to modulate
amphetamine-induced c-fos expression in Dyn-SP+ cells,
depending on the context in which amphetamine is given.
For example, 5-HTR agonists induce c-fos expression
primarily in Dyn-SP+ cells, an effect that is reversed by
5-HTR or D1R antagonists (Li and Rowland 1993; Gardier
et al. 2000), suggesting 5-HT as a candidate. Another
candidate is acetylcholine, as intrastriatal infusions of
muscarinic receptor agonists and antagonists differentially
Fig. 7 Expression of c-fos mRNA in the dorso-caudal CPu after pre-
treatment with the NMDAR antagonist ifenprodil. Top panels (a–c)
depict the total number of c-fos+ cells and bottom panels (d–f) depict
the number of c-fos/Dyn-SP+ cells (white circles) or c-fos/Enk+ cells
(black squares) as a function of treatment and environmental condi-
tion. Ifenprodil significantly decreased the total number of c-fos+ cells
in the home/amphetamine group (panel b, F2,17 ¼ 5.43, p ¼ 0.02), the
novel/amphetamine group (panel c, F2,18 ¼ 3.86, p ¼ 0.04) but not the
novelty stress group (panel a, F2,9 ¼ 1.09, p ¼ 0.38). Interestingly,
ifenprodil significantly decreased the number of c-fos/Dyn-SP+ in the
home/amphetamine group (panel e, F2,16 ¼ 4.82, p ¼ 0.02) but not
the novel/amphetamine group (panel f, F2,18 ¼ 1.06, p ¼ 0.37) nor the
novelty stress group (panel d, F2,9 ¼ 0.57, p ¼ 0.59). Ifenprodil sig-
nificantly decreased the number of c-fos/Enk+ in the novel/amphet-
amine group (panel f, F2,17 ¼ 6.53, p ¼ 0.008) but not the novelty
stress group (panel d, F2,9 ¼ 0.06, p ¼ 0.95). *, differs from 0 mg/kg
(p < 0.05, Dunnett’s-test).
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regulate amphetamine-evoked neuropeptide expression in
Dyn-SP+ cells (Wang and McGinty 1997).
Finally, another interesting possibility is that the ability of
DA and glutamate to regulate c-fos expression in Dyn-SP+
cells is contingent on the activation state of Enk+ cells. In the
novel condition, D2R and NR2B subunit-selective NMDAR
antagonists are highly effective at blocking amphetamine-
induced c-fos expression in Enk+ cells. A consequence of
this antagonism could be dis-inhibition of Dyn-SP+ cells,
which would manifest itself as an apparent loss of an effect
of these antagonists. In support of this, in vivo electrophys-
iology studies have found that D2R antagonism increases
cortical stimulation-evoked excitatory post-synaptic poten-
tials (EPSPs) in striatal neurons, which leads to a facilitation
in D1R-mediated neuronal activity (West and Grace 2002).
Regulation of c-fos expression in Enk+ cells evoked
by amphetamine given in a novel environment
Amphetamine-evoked c-fos expression in Enk+ cells was
extremely sensitive to all of the antagonists tested. Indeed,
the lowest dose of every antagonist tested significantly
reduced c-fos expression in Enk+ cells, but the same dose
had no effect on c-fos expression in Dyn-SP+ cells.
Furthermore, D2R and NR2B subunit-selective NMDAR
antagonists dose-dependently reduced c-fos expression in
Enk+ cells, but had no effect on c-fos expression in Dyn-SP+
cells in the novel environment.
The receptors involved in the ability of psychostimulant
drugs to induce IEGs in Enk+ cells have never been studied.
However, stimulation of corticostriatal afferents induces c-fos
preferentially in Enk+ cells, an effect that is blocked by
NMDAR antagonists (Berretta et al. 1997; Parthasarathy and
Graybiel 1997; Sgambato et al. 1997), and is thought to
occur via activation of the extracellular signal-regulated
kinase/mitogen-activated protein kinase (ERK1/2/MAPK)
signaling pathway (Sgambato et al. 1998a,b; Gerfen et al.
2002). DA modulates the ability of glutamate to activate this
pathway, because D1R antagonists block and D2R antago-
nists potentiate cortical stimulation-evoked c-fos expression
in the striatum (Fu and Beckstead 1992; Liste et al. 1995;
Berretta et al. 1997, 1999). Given that amphetamine admin-
istration in a novel environment is accompanied by strong
activation of the neocortex, it is reasonable to hypothesize
that under these conditions amphetamine induces c-fos
expression in Enk+ cells via NMDAR-mediated activation
of intracellular signaling cascades. The effects of NMDAR
antagonists reported here support this idea. It is less clear,
however, why D1R and D2R receptor antagonists were also
more effective in reducing c-fos expression in Enk+ cells
than in Dyn-SP+ cells.
It is possible that the mechanism by which cortical
stimulation induces c-fos expression in Enk+ cells is different
than the mechanism by which amphetamine in a novel
environment induces c-fos in Enk+ cells. For example, DA
can potentiate the post-synaptic effects of glutamate, and the
relative balance of DA and glutamate receptor signaling may
determine which intracellular signaling cascades are engaged
in what cells (Carlsson and Carlsson 1990; Lindefors and
Ungerstedt 1990; Gerfen et al. 2002). Thus, when cortical
activation is coupled with high levels of DA release (as
would occur following amphetamine administration in a
novel environment), perhaps NMDAR-mediated activation
of IEG expression in Enk+ cells is facilitated, and this is
highly susceptible to both DA and glutamate receptor
antagonism. Further studies are needed to explore the
manner in which DA and glutamate interact to modulate
the mechanisms that underlie IEG expression in Enk+ cells
under different conditions.
In the present study, antagonists were injected systemically
and therefore it is possible that c-fos expression was
decreased through actions at sites outside the CPu. We know
of no studies on the effects of direct intrastriatal infusions of
these antagonists specifically on psychostimulant-induced
IEG expression in neurologically intact animals. However,
intrastriatal infusions of D1R antagonists decrease apomor-
phine-induced IEG expression in intact animals and intra-
striatal infusions of D1R, D2R or NMDAR antagonists
decrease IEG expression induced by direct D1R– and
D1R + D2R agonists in dopamine denervated animals
(Keefe and Gerfen 1995, 1996). NMDAR antagonists also
decrease psychostimulant-induced IEG expression in disso-
ciated striatal cell cultures (Konradi et al. 1996). Further-
more, it is unlikely that D1R antagonists acted in the cortex
to block corticostriatal glutamate release because D1R
antagonists do not alter amphetamine-induced Fos expres-
sion in the cerebral cortex (Graybiel et al. 1990) and it is
unlikely that the NMDAR antagonists acted in the substantia
nigra to block dopamine release because intranigral infusions
of NMDAR antagonists potentiate, rather than decrease, D1R
agonist-induced c-fos expression in unilateral 6-OHDA-
lesioned rats (Fenu et al. 1995; McPherson and Marshall
2000). In addition, c-fos mRNA expression in the region of
anterior cingulate that projects to dorso-caudal CPu was
analyzed in the present study and there were no major
differences in cortical c-fos expression as a function of
antagonist pre-treatment (except for a decrease in cortical
c-fos expression seen in the highest dose of CPP in the novel
environment, data not shown). We conclude, therefore, that
the effects of antagonists reported here are likely due to their
actions within the CPu, but further studies will be necessary
to test this hypothesis.
Regulation of novelty stress-evoked c-fos expression
Novelty stress also induced c-fos expression in both Dyn-
SP+ and Enk+ cells (i.e. 68% of c-fos+ cells were Dyn-SP+
and 33% of c-fos+ cells were Enk+). The total number of
c-fos+ cells was much less than that seen after amphetamine
administration in a novel environment, but the proportion of
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c-fos/Dyn-SP+ and c-fos/Enk+ cells was similar. This
suggests that amphetamine may simply amplify the actions
of novelty stress. However, the effects of the antagonists do
not support this otherwise straight-forward interpretation.
Only D1R antagonists reduced novelty stress-induced c-fos
expression in either cell population. The fact that D2R and
NMDAR antagonists were relatively ineffective suggests that
the ability of novelty stress to induce c-fos in either cell
population may involve different mechanisms than is the
case with amphetamine. Perhaps these differences also
involve the relative balance of DA and glutamate signaling,
or interactions with other neurotransmitters systems.
Conclusion
The most important message from the present study is that
different mechanisms are likely involved in the ability of
amphetamine or novelty stress to induce c-fos expression in
different cell populations in the CPu, depending on environ-
mental context. Given that the ability of drugs of abuse to
induce IEGs represents a critical step in the development of
many forms of drug experience-dependent neuroplasticity
related to addiction (Nestler et al. 1993; Hyman and Malenka
2001), it will be critical to delineate how the pharmacological
effects of drugs interact with environmental factors to
determine which neurotransmitters systems, receptors and
intracellular signaling cascades are engaged to alter gene
expression.
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